Showing 271-280 of 328 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Randomized trial of semaglutide for diabetic kidney disease in type 1 diabetes | University of Washington | Ian De Boer | Improving Lives | 01-September-2023 to 31-August-2026 | $2.107.411,00 |
| Effectiveness and safety of sotagliflozin in slowing kidney function decline in persons with type 1 diabetes and moderate to severe diabetic kidney disease: The SUGARNSALT Trial | Joslin Diabetes Center Inc. | Alessandro Doria | Improving Lives | 01-January-2024 to 31-December-2028 | $8.913.450,00 |
| Reducing Glycemic Variability to Improve Cardiovascular Health in Type 1 Diabetes | Rector & Visitors of the University of Virginia | William Horton | Improving Lives | 01-December-2022 to 30-November-2025 | $858.072,00 |
| Preclinical evaluation of SERCA2 activators for pancreatic beta-cell protection in T1D | Neurodon LLC | Russell Dahl | Cures | 01-June-2022 to 31-May-2026 | $920.000,00 |
| Developing fusion therapeutics to selectively target beta cell surface receptors for treating T1D | UT Southwestern | Wen-hong Li | Cures | 01-July-2022 to 30-June-2025 | $900.000,00 |
| Acetazolamide and Tubuloglomerular Feedback in Persons with Type 1 Diabetes: A Clinical Trial | University of California, San Diego | Charles Ginsberg | Improving Lives | 01-November-2022 to 31-October-2026 | $1.356.726,45 |
| Harnessing zinc-tropic agents for targeted delivery of therapeutics to islet beta cells for preventing or treating T1D | UT Southwestern | Wen-hong Li | Cures | 01-August-2022 to 31-October-2025 | $900.000,00 |
| Novel mechanism and method to control T cell mediated autoimmunity in type 1 diabetes | Case Western Reserve University | Parameswaran Ramakrishnan | Cures | 01-June-2022 to 31-May-2026 | $600.000,00 |
| Evaluating the dose and toxicity of telaprevir in a rat model of T1D | Joslin Diabetes Center Inc. | Rohit Kulkarni | Cures | 01-June-2022 to 31-December-2025 | $494.000,00 |
| GPR75, a novel actor in beta cell regeneration | New York Medical College | Ercument Dirice | Cures | 01-April-2022 to 31-March-2026 | $750.000,00 |